ETIDIoH<p><strong>Structural basis of broad #protection against <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/influenza-2/" target="_blank">#influenza</a> virus by a <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/human-2/" target="_blank">#human</a> #antibody targeting the #neuraminidase active site via a recurring motif in CDR H3</strong></p><p>Source: BioRxIV, <a href="https://www.biorxiv.org/content/10.1101/2024.11.26.625467v1" rel="nofollow noopener noreferrer" target="_blank">https://www.biorxiv.org/content/10.1101/2024.11.26.625467v1</a> </p><p><strong><em><span>Abstract</span></em></strong><br>Influenza viruses evolve rapidly, driving <strong>seasonal epidemics and posing global pandemic threats</strong>. While <strong>neuraminidase (NA) </strong>has emerged as <strong>a vaccine target</strong>, shared molecular <strong>features of NA antibody responses are still not well understood</strong>. Here, we describe <strong>cryo-electron microscopy structures </strong>of the <strong>broadly protective human antibody DA03E17</strong>, which was previously identified from an <strong>H1N1-infected donor</strong>, in complex with NA from <strong>A/H1N1, A/H3N2</strong>, and <strong>B/Victoria-lineage viruses</strong>. DA03E17 targets the highly conserved NA active site using its long CDR H3, which features a DR (Asp-Arg) motif that engages catalytic residues and mimics sialic acid interactions. We further demonstrate that this motif is conserved among several <strong>NA active site-targeting antibodies</strong>, indicating a <strong>common receptor mimicry strategy</strong>. We also identified potential <strong>antibody precursors </strong>containing this DR motif in all donors of a healthy human donor BCR database, highlighting the prevalence of this motif and its potential as vaccine targeting. Our findings reveal shared molecular features in NA active site-targeting antibodies, offering insights for NA-based universal influenza vaccine design.</p><p>____</p><p><span></span></p><p><a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/ah3n2-2/" target="_blank">#aH3n2</a> <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/abstract/" target="_blank">#abstract</a> <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/biology-2/" target="_blank">#biology</a> <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/h1n1pdm09/" target="_blank">#h1n1pdm09</a> <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/health/" target="_blank">#health</a> <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/immunology-2/" target="_blank">#immunology</a> <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/influenza-a/" target="_blank">#influenzaA</a> <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/monoclonal-antibodies/" target="_blank">#monoclonalAntibodies</a> <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/research-2/" target="_blank">#research</a> <a rel="nofollow noopener noreferrer" class="hashtag u-tag u-category" href="https://etidioh.wordpress.com/tag/vaccine/" target="_blank">#vaccine</a></p>